Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Fabiani C, Sota J, Sainz-de-la-Maza M, Pelegrín L, Emmi G, Lopalco G, et al. Effectiveness of TNF-α blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clin Exp Rheumatol. 2020;38:1138–44.
2. Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, et al. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Brit J Ophthalmol. 2021;105:1256–62.
3. Braithwaite T, Adderley NJ, Subramanian A, Galloway J, Kempen H, John Gokhale K, et al. Epidemiology of scleritis in the United Kingdom From 1997 to 2018: population‐based analysis of 11 million patients and association between scleritis and infectious and immune‐mediated inflammatory disease. Arthritis Rheumatol. 2021;73:1267–76.
4. Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. 2005;50:351–63.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685.